The potential safety concerns related to the use of ROCK inhibitors, together with the fact that the currently developed compounds have shown only moderate kinase selectivity (either against the two isoforms ROCK1 and ROCK2 or to a number of other kinases), have limited their use as systemic therapies in cancer clinical trials. The gene discussed is ROCK2; the disease is cancer.